INTRODUCTION
While tumors which are confined to their site of origin may often be cured by local treatment such as surgery or conventional external beam irradiation, cancer which has spread to locations distant from the primary tumor requires a treatment which is applied to the whole body of the patient. Total body irradiation is effective in the management of leukemia but normal tissue intolerance restricts the radiation dose which can be given, so that it cannot be used against less radiosensitive neoplasia. Biologically targeted radionuclide therapy is an alternative method of systemic irradiation treatment which circumvents the two problems of widespread distribution of disease and the intolerance of normal tissues.
Targeted radiotherapy uses a molecular vehicle which either localises on the surface of malignant cells or is preferentially accumulated within them. For many tumours, monoclonal antibodies or their fragments represent the only targeting agents. With the notable exception of Bcell lymphoma [1, 2] , clinical applications of these radiolabelled macromolecules have generally been unsatisfactory due to low tumor specificity of targeted epitopes, limited penetration into tumors, and the provocation of anti-mouse immunoglobulin responses. These considerations favour the use of nonimmunogenic small molecules with higher uptake in tumours. These criteria are fulfilled by peptides, meta-iodobenzylguanidine (MIBG), and sodium iodide (NaI), which are readily available in radioiodinated form. MIBG and NaI have been used extensively for the treatment of neural crest-derived tumors (neuroblastoma and phaeochromocytoma) and thyroid carcinoma, respectively.
The new challenge is to enhance targeted radiotherapy by combining it with the transfer into tumour cells of genes encoding specific transporters. The success of this approach has been demonstrated in model systems. Efforts are now underway to optimise tumour to normal tissue uptake ratios; to limit the expression of transporter genes to malignant sites; and to compare the therapeutic potential of α-and β-emitting radionuclides conjugated to tumour-seeking agents. These investigations will determine optimal promoter/transgene/radionuclide combinations for effective human anticancer gene therapy.
TRANSDUCTION OF ANTIGEN ENCODING GENES FOR ANTIBODY TARGETING
The efficacy of radiolabelled antibodies is not due to radiation kill alone [3] but results also from the cytotoxic effects of unlabelled antibody, namely apoptosis, complement-mediated cytolysis and antibody-dependent cellular cytotoxicity. This type of treatment is proving to be useful in the management of B-cell lymphomas [4] which are more radiosensitive than solid tumours. They have a propensity to apoptose after radiation insult and have limited capacity for the repair of sublethal damage. However, radioimmunotherapy of other tumour types has been less impressive. An average value, computed from a wide range of articles, for the accumulation of radiolabelled antibodies-0.005% per gram of the administered activity-is insufficient for tumour sterilisation [5] . An impediment to radioimmunotherapy is the sparsity of antigen presentation on the membranes of tumour cells.
This problem has been addressed by transfection of genes to induce tumour cells to express high concentrations of membrane-associated epitopes which have affinity for monoclonal antibodies. Radiolabelled antibodies directed against carcinoembryonic antigen (CEA) have been used extensively in experimental and clinical detection and treatment of various tumours (reviewed by Buchsbaum and Curiel [6] ). Raben et al [7] have demonstrated that adenovirus-mediated gene transfer resulted in high levels of CEA expression in vitro in tumour cells that did not constitutively express CEA, rendering those cells capable of binding radiolabelled COL-1 anti-CEA antibody. They have further demonstrated the applicability of this approach in vivo in nude mice resulting in enhanced, radiolabelled, antibody localisation to tumours transduced by intratumoural injection of the recombinant virus.
After extensive preclinical testing, the most exciting clinical data has come from the use of radioimmunotherapy in the treatment of lymphoma and haematological malignancies and it would now appear highly likely that radioimmunotherapy in combination with gene transfer will play a major role in treatment strategies for these diseases. Results in solid tumours are improving. However, much progress remains to be made before RIT becomes a component of standard practice for common malignancies in the clinic.
FACILITATION OF PEPTIDE TARGETING BY RECEPTOR GENE EXPRESSION
Tumour-targeting peptides offer several advantages over antibodies such as improved penetration characteristics, ease of labelling, and lack of immunogenicity. Several studies show the feasibility of inducing the expression of receptors by tumour cells to improve the accumulation of toxic radionuclides transported by a variety of peptide ligands. For example, virus-assisted gene transfer stimulated the expression of the receptor for thyrotropinreleasing hormone (TRH) with subsequent binding of radiolabelled TRH [8] . Unfortunately, this tripeptide has a short biological half-life in serum and loses receptor affinity after conjugation to radionuclides. Using in vitro and in vivo models, Rogers et al [9] have demonstrated the potential of a seven-peptide analogue of bombesin to target tumour cells transfected with the gene encoding gastrin releasing peptide receptor. This ligand is attractive because it is readily bound to several different radionuclides, maintains receptor binding affinity and exhibits in vivo stability. Recently, Stackhouse et al [10] introduced a greater level of sophistication to this scheme by placing the expression of the GPR transgene under the control of promoter elements of one of two different genes-erbB-2 and MUC1-which are overexpressed in a number of tumours. This strategy was successful in restricting GPR expression to human breast and cholangiocarcinoma cell lines thereby demonstrating the potential for tumour-specific targeting with radiolabelled peptide. An exciting application of the control of expression by the MUC1 carcinoma-promoter has been described by Chen et al [11] . They eliminated six logs of contaminating cancer cells from haemopoietic stem cell preparations by ganciclovir treatment after adenoviral-mediated transduction of HSV-tk gene under control of the MUC1 promoter. This study illustrates the potential of the gene transfer approach to the purging of marrow or peripheral blood stem cells.
An attractive means of improving the specificity of targeting is to express a nonhuman receptor on tumour cells and target these with a xenogeneic molecule. For example, the murine glycoprotein, interleukin-4 (IL-4), does not bind to the human IL-4 receptor nor does the human IL-4 have affinity for the murine receptor. The mouse receptor cDNA has been expressed in heterologous cells, resulting in a five-fold increase in binding of ligand to transfectants [12] . It is hoped that this promising strategy for the transport of therapeutic radionuclides can be developed using xenogeneic systems which involve smaller targeting agents such as peptides or steroids [13] .
Somatostatin receptors, which are expressed on many tumours of neuroendocrine origin, constitute another peptide target which may be exploitable for radionuclide therapy. Octreotide is an octapeptide analogue of somatostatin which has greater stability in plasma than the natural ligand [14] . Rogers et al [15] recently employed recombinant adenoviral vectors to induce somatostatin receptors on human nonsmall cell lung cancer cells which were grown as xenografts. Tumour localisation was demonstrated using [ 111 In]-labelled octreotide and therapeutic efficacy was obtained with [ 90 Y] octreotide. This is the first illustration in vivo of the effectiveness of a radiolabeled peptide targeted to a receptor expressed on the surface of tumor cells following gene transfer. It is expected that these studies will form the basis of future therapeutic investigations using gene transfer to enhance tumour targeting by radiolabelled octreotide.
RADIOHALIDE CONCENTRATION VIA THE SODIUM IODIDE SYMPORTER
Unlike the above schemes for radionuclide targeting, sodium radioiodide (Na 131 I) therapy requires no radiochemical synthetic procedure. Most well-differentiated thyroid tumours retain iodide-concentrating capacitymediated by the sodium (Na) iodide (I) symporter (NIS). Therefore, Na 131 I is used to ablate postsurgical remnants and to treat recurrent and metastatic disease. The overall prognosis following radioiodine therapy is good for differentiated thyroid cancer. This is the most basic, yet most efficacious form of radionuclide therapy to date.
Cloning and characterisation of the sodium iodide symporter (NIS) gene has stimulated cytoreductive gene therapy based on NIS gene transfer followed by the administration of radioiodide. Transfer of the NIS gene into a variety of nonthyroidal cancer cell lines has induced iodide uptake activity and cytotoxicity [16, 17, 18] . Following PSA promoter-mediated NIS gene delivery, prostatespecific iodide accumulation was achieved in prostate cancer cells that was sufficient to attain a therapeutic response of 131 I in vitro and in vivo [19, 20] . These observations indicate that, following thyroid blockade, it may be possible to deliver Na 131 I to transfected, NISexpressing, tumour cells with minimal uptake of radioactivity in normal tissues.
However, rapid efflux of radioiodide from NIS gene transfectants imposes a severe limitation on tumor cell killing. Means of circumventing this problem are under investigation. Unlike NIS-transfected tumor cells, thyrocytes exhibit, in addition, peroxidase activity which is responsible for the oxidation of accumulated iodide, leading to its conjugation to tyrosyl residues of thyroglobulin and prolonged entrapment within the cell. Huang et al [21] reported an increase in radioiodide uptake and retention and enhanced apoptosis in nonsmall cell lung cancer cells transfected with both NIS and thyroperoxidase genes.
As well as iodide, several other monovalent anions have the affinity for NIS [22] . Those with ionic radii similar to iodide are more readily transported [23] . (Table 1) is influenced by the expected intracellular residence time of the radioactivity and the range of cross fire radiation needed to sterilise clumps of tumor cells of different sizes. Ideally, the physical half-life of the radionuclide should closely match its intracellular half-time of retention. Therefore, an alternative tactic to overcome the rapid efflux of iodide from NIS transfectants is to employ radiohalides with short t 1/2 values. Experimental evidence indicates that the highly radiotoxic α-emitter astatide (Na 211 At) has an affinity for NIS-expressing cells [24] and could be an alternative radiohalide to [ 131 I]-iodide for NIS-based endoradiotherapy.
The demonstration that NIS was expressed not only in the lactating mammary gland but also in more than 80% of breast cancer [25] indicated that radioiodide may be an option for the diagnosis and treatment of mammary gland malignancies. To assess the feasibility of imaging NIS-expressing tumors, we compared the rate of loss of actively transported 131 − could be a potent therapeutic agent because it is able to deliver a dose 4.5 times higher than 131 I [27] .
Exploitation of the NIS has potentially important applications in the management of breast cancer and other tumor types. Future directions in NIS-targeting will include the enhancement of radiohalide retention in tumors, circumvention of normal tissue uptake by differential regulation of NIS expression, and the investigation of tumor-imaging agents. 
TRANSFECTION OF THE NORADRENALINE TRANSPORTER GENE FOR MIBG-TARGETED RADIOTHERAPY
One impediment to the wider application of radioiodide therapy is the localisation of radioactivity in nontarget organs. This has prompted the search for tumoraffinic radiolabelled compounds which have a low tendency to deiodinate in vivo. One such agent is [ 131 I]-labelled meta-iodobenzylguanidine ([ 131 I]MIBG). The structure of MIBG is based on those of the adrenergic neurone blockers guanethidine and bretylium [28] (Figure 2 ). Because MIBG has high affinity for the noradrenaline transporter (NAT) [29] , it is used in the imaging and treatment of tumors derived from the neural crest, such as neuroblastoma and phaeochromocytoma. NAT expression is predictive for MIBG uptake capacity [30] and quantification of NAT mRNA could be used for the selection of patients for MIBG therapy [31] . [33] . While presently, there is only an in vitro demonstration of the effect, these results are promising and indicate that it may be possible to elevate the intracellular levels of the radiopharmaceutical so that cure, rather than temporary control of tumour growth, could be the outcome. Given an appropriate delivery vehicle and tumour-specific control of expression, the introduction of exogenous NAT may make more neuroblastoma tumours amenable to MIBG therapy. In collaboration with the Gaslini Institute, Genoa, we are currently developing immunoliposomal systems for the delivery to neuroblastoma of NAT cDNA and MIBG. [ 131 I]MIBG is one of the best agents for targeted radiotherapy but its utility is restricted to a small number of NAT-expressing tumour types. We observed that after transfection of the NAT gene into a human glioma cell line, it actively concentrated [ 131 I]MIBG resulting in substantial toxicity, demonstrating the potential of gene therapy-assisted MIBG-targeted radiotherapy for the treatment of nonneuroectodermal tumors [34] . These findings are extremely encouraging for the development of NAT gene transfer-mediated [ 131 I]MIBG therapy. We expect the first clinical applications to be in the treatment of glioma or prostate carcinoma.
Targeting gene expression specifically to tumour cells, is one of the most important goals of research in cancer gene therapy. Appropriate control elements for the expression of transgenes that facilitate targeted radiotherapy are radiation-inducible gene promoters. Aspects of this type of gene regulation are reviewed by Robson in this issue.
Telomerase is the most common general marker of cancer cells and its activity has been detected in every major category of human malignancy, whereas normal somatic tissues have negligible activity [35, 36, 37, 38] . Therefore, an alternative method of specifying gene expression to malignant cells is provided by the telomerase promoters. Unfortunately, mammalian promoter elements are generally inefficient transcriptional activators [39] . However, we observed 17-fold enhancement of [ 131 I]MIBG uptake by UVW glioma cells transfected with the NAT gene whose expression was driven by the human telomerase RNA (hTR) promoter. This level of induction was 70% of the uptake achieved by a strong viral promoter and was sufficient to sterilise all clonogens in multicellular spheroids, suggesting that hTR-regulated expression of NAT may be an effective therapeutic strategy [40] .
EVALUATION OF RADIOLOGICAL BYSTANDER EFFECTS
It is unlikely that gene therapy technology will achieve 100% transfection of cells in a clinical tumour. Bystander effects are therefore an important requirement for effective gene therapy. Current gene therapy is mostly based on prodrug activation, with bystander effects dependent on gap junctions which often diminish with tumour progression [41] . Novel systems providing a freely diffusable product are under investigation [42] . Multicellular spheroids are substantially more susceptible than monolayer cultures to the lethal effects of 131 I β-radiation [43] . The increased effectiveness of radionuclide treatment of cellular aggregates is due to the enhanced efficiency of absorption of decay energy in threedimensional cultures [34, 44] . This cross fire irradiation phenomenon (Figure 3) is an especially attractive feature of gene therapy schemes involving cellular concentration of radionuclides since gene transfer is notoriously inefficient, necessitating a mechanism which achieves bystander cell kill. The radiological bystander effect resulting from radiation cross fire provides exciting new possibilities, especially when transfection rates are low. This and other bystander effects require further investigation, for which a suitable experimental model would be very valuable.
Very recently, we have developed a modified spheroid system-transfectant mosaic spheroids (TMS) [45] which is well suited to the experimental investigation of bystander effects (Figure 4) . TMS are hybrids formed by coculturing gene-transfected and nontransfected (but otherwise identical) cells in controlled proportions. This allows the experimental simulation of small tumours in which a range of proportions of cells have been transfected. The mosaic spheroid model is used in our investigation of the radiological bystander effect to quantify the effects of radiation cross fire as a function of the proportion of the cells transfected.
To examine the utility of this system, we prepared TMS from glioma cells transfected with the NAT gene or the GFP gene. Cell killing by [ 131 I]MIBG was proportional to the percentage of MIBG-uptaking cells ( Figure 5 ). We conclude that TMS provide a useful model for assessment of the effectiveness of targeted radiotherapy in combination with gene therapy when less than 100% of the target cell population is expressing the NAT transgene [46] .
CONCLUSION
Despite the attractiveness of the concept of sterilising cancer cells by means of the specific delivery of radionuclides, targeted radiotherapy has been applied only to a few malignant diseases with suitable biochemical features. The advent of gene transfer technology, promises to widen the scope of targeted radiotherapy by enabling the expression by tumour cells of membrane-bound proteins which actively accumulate radiopharmaceuticals.
Recent research findings augur well for the development of gene transfer to enable the targeting of a variety of tumour types with low molecular weight radiopharmaceuticals. It is envisaged that this approach combined with conventional therapeutic modalities, will improve cancer treatment in the new century. The immediate goals are to achieve efficient, tumour-specific, gene expression and efficacy in animal models before proceeding to clinical evaluation.
We envisage that the first clinical usage of this combined approach will be for the treatment of regionally confined malignancies such as glioma and bladder carcinoma or for the purging of bone marrow or peripheral blood stem cells prior to autologous rescue. To turn these dreams into reality, we must now develop efficient and specific vectors for the delivery of therapeutic transgenes.
